Patents Issued in August 23, 2018
-
Publication number: 20180235886Abstract: Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic.Type: ApplicationFiled: August 18, 2016Publication date: August 23, 2018Applicant: Mayo Foundation for Medical Education and ResearchInventors: Svetomir N. Markovic, Wendy K. Nevala
-
Publication number: 20180235887Abstract: Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.Type: ApplicationFiled: January 11, 2018Publication date: August 23, 2018Applicant: PROTHENA THERAPEUTICS LIMITEDInventors: Patrick GARIDEL, Isaac Craig HENDERSON, Pamela KLEIN
-
Publication number: 20180235888Abstract: The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.Type: ApplicationFiled: April 20, 2018Publication date: August 23, 2018Inventors: Simon Bjerregaard Jensen, Per Sauerberg, Flemming S. Nielsen, Betty L. Pedersen, Erik Skibsted
-
Publication number: 20180235889Abstract: An object of the present invention is to provide an orally disintegrating tablet (super-rapid disintegrating tablet) that is heavy and relatively thin, and has an extremely high disintegrability (short disintegration time), and a high tablet hardness, and to provide a simple method for the production of said super-rapid disintegrating tablet without such a complicated process as freeze-drying. This invention relates to an orally disintegrating tablet having a specific surface area of from 1.50 to 4.00 mm2/mg and a weight of from 100 to 300 mg, particularly having a disintegration time in water of 7 seconds or less and an oral disintegration time of 6 seconds or less, a method for the production of said orally disintegrating tablet, and to a disintegrative particulate composition for use in said method.Type: ApplicationFiled: August 16, 2016Publication date: August 23, 2018Inventors: Tomohito OKABAYASHI, Atsuhiro UETOMO, Naohiro HASHIKAWA, Takahiro HIRAMURA, Tetsuro MORITA, Kimiko IKEDA
-
Publication number: 20180235890Abstract: The present invention discloses a rice bran sterol sugar-coated tablet comprising rice bran sterol, a filler and a coating agent, wherein a mass ratio of the rice bran sterol, the filler and the coating agent is 1:3.9-4.5:1.30-1.35. The filler is composed of starch, dextrin, talcum powder, calcium carbonate, microcrystalline cellulose, starch slurry, carboxymethyl starch sodium, magnesium stearate and silicon dioxide in a mass ratio of 1.29-1.5:0.5-0.71:1:1:0.24-0.25:1.86-2.25:0.16-0.18:0.028-0.03:0.14-0.17, and the coating agent is composed of white sugar, gum, gelatin, pigment and Chinese insect wax in a mass ratio of 201-249:5.56-8:1:0.06-0.07:1. The rice bran sterol sugar-coated tablet may be used for treating periodontitis and acute pharyngolaryngitis and has obvious treatment effects on peniculus system inflammations, and is harmless to the human body.Type: ApplicationFiled: April 18, 2018Publication date: August 23, 2018Applicant: Hangzhou Yipin Xinwufeng Pharmaceutical Co., Ltd.Inventors: Weixing Jiang, Long Jiang, Aiqin Shi, Zhiqiang Mo
-
Publication number: 20180235891Abstract: Described herein are pharmaceutical enteric soft capsules that do not contain gelatin as a film-forming polymer. In particular, compositions and methods for manufacturing enteric soft capsules comprising carrageenans as film forming polymers are disclosed.Type: ApplicationFiled: April 23, 2018Publication date: August 23, 2018Inventors: Qi FANG, Josh HEFLIN, Madhu HARIHARAN
-
Publication number: 20180235892Abstract: A hard or soft capsule is disclosed comprising a shell and a fill material, wherein the shell comprises an interpenetrating network comprising a silk polymer and a film-forming natural polymer. A method of making a hard or soft capsule is also disclosed, comprising dissolving a silk protein in a solvent system to form a solubilized silk protein solution; mixing the solubilized silk protein solution with a film-forming natural polymer to form a homogenous shell material; and encapsulating a fill material with the homogenous shell material.Type: ApplicationFiled: April 23, 2018Publication date: August 23, 2018Inventors: Tatyana DYAKONOV, Derek BUSH, Saujanya L. GOSANGARI, Chue Hue YANG, Shingai MAJURU, Aqeel FATMI
-
Publication number: 20180235893Abstract: An improved process of making a benefit agent delivery particle and consumer products incorporating such particles are disclosed. The process comprises the steps of providing a first composition of water phase 1, water phase 2 and water phase 3. Water phase 1 comprises water and an initiator; water phase 2 comprises water, a water-soluble or dispersible amine(meth)acrylate or hydroxyl(meth)acrylate and a multifunctional (meth)acrylate. Water phase 3 comprises water, and carboxyalkyl(meth)acrylate and a base or quarternary ammonium acrylate. The first two water phases are combined to prereact the hydroxy- or amine(meth)acrylate and the multifunctional (meth)acrylate to form a multifunctional hydroxyl-amine(meth)acrylate pre-polymer.Type: ApplicationFiled: April 24, 2018Publication date: August 23, 2018Inventors: Hanwei ZHANG, Todd Arlin SCHWANTES, Katie Ann HOBART, Diane Jean WILLIAMSON
-
Publication number: 20180235894Abstract: Disclosed herein is a platelet membrane-coated nanovehicle having an inner core comprising a drug delivery matrix, and an outer shell platelet membrane coating the inner core. The inner core can be any drug delivery matrix capable of delivering a therapeutic agent to a cell. The outer shell platelet membrane can be a natural or synthetic membrane comprising platelet proteins capable of interacting with cancer cells. Also disclosed is a method for treating cancer in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein. Also disclosed is a method for treating vascular disease in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein.Type: ApplicationFiled: August 12, 2016Publication date: August 23, 2018Inventors: Zhen GU, Quanyin HU
-
Publication number: 20180235895Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.Type: ApplicationFiled: April 20, 2018Publication date: August 23, 2018Inventors: Ricardo Alberto VARGAS RINCON, Joseph REIZ
-
Publication number: 20180235896Abstract: The invention relates to nanoparticles for the systemic or topical delivery of lipophilic diagnostic or therapeutic agents to a subject in need thereof. The nanoparticles of the invention comprise a water soluble polymer and at least one of a biocompatible lipid and a lipophilic agent. The invention further relates to ophthalmic treatment using the nanoparticles of the invention. In addition, the invention pertains to compositions and formulations comprising the nanoparticle of the invention. Such formulation may be an eye drop formulation.Type: ApplicationFiled: August 11, 2016Publication date: August 23, 2018Applicant: Eyesiu Medicines B.V.Inventors: Pieter Jaap Gaillard, Jacob Rip
-
Publication number: 20180235897Abstract: Provided herein are peptides comprising an amino acid sequence having at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). These cationic peptides inhibit PKM2 methylation and may be used in the treatment of breast cancer and other diseases or conditions in which PKM2 is overexpressed. Such PKM2 peptides may be delivered to cancer cells using pH sensitive unimolecular nanoparticles comprising anionic polymers.Type: ApplicationFiled: February 8, 2018Publication date: August 23, 2018Applicant: Wisconsin Alumni Research FoundationInventors: Shaoqin GONG, Wei XU, Yuyuan WANG, Fabao LIU
-
Publication number: 20180235898Abstract: The invention provides methods of making and using compositions comprising a polymer shell designed to deliver polypeptides to selected environments. In embodiments of the invention, different environmental conditions are harnessed to allow the selective degradation of the polymer shell and the consequential release of one or polypeptides encapsulated therein. In illustrative embodiments, polymer components of the shell are interconnected by peptide-containing crosslinker to moieties, linkages which maintain the integrity of the polymer shell under certain enviromental conditions, but can also be cleaved when combined with a selected protease.Type: ApplicationFiled: April 24, 2018Publication date: August 23, 2018Applicant: The Regents of the University of CaliforniaInventors: Yunfeng Lu, Tatiana Segura, Suwei Zhu, Jing Wen
-
Publication number: 20180235899Abstract: A device for delivery of a first therapeutic agent and a second therapeutic agent to a site in epithelial tissue includes a first layer having a first, freeze-dried polymeric matrix having first and second opposed surfaces, formed by a composition including chitosan, a hydration promoter, a particle adhesion inhibitor, and a particle aggregation inhibitor, and a plurality of first particles embedded within the first matrix so as to be directly surrounded by, and in contact with, the first matrix, the first particles containing the first therapeutic agent and having a coating around the first therapeutic agent, the coating including chitosan. The device further includes a second layer, adjacent to the first layer, having a second, freeze-dried polymeric matrix containing the second therapeutic agent, the first layer and/or the second layer is configured to be attached to the site in the epithelial tissue.Type: ApplicationFiled: February 16, 2018Publication date: August 23, 2018Inventors: Manijeh Nazari Goldberg, Aaron Manzi, Brandon LaPorte, Amritpreet Birdi
-
Publication number: 20180235900Abstract: The medical devices of the present disclosure are filled reservoirs such as a cylinder comprised of a polymer film which contains a reservoir of active agent, plus excipient, in some cases, for disease prevention, treatment, and/or contraception. The polymer film is permeable to the active agent after subcutaneous implantation of the device into a body. The cylinder is comprised by the lamination of one or two polymer films which are ultrasonically welded to contain the drug material. The use of an ultrasonic welding process enables sealing of the polymer films to create the closed cylinder. The medical device is useful for long term disease prevention, such as prevention of HIV infection.Type: ApplicationFiled: February 6, 2018Publication date: August 23, 2018Inventors: Stephanie Lynn Swarner, Leah Johnson, Robert F. Praino, JR., Phillip Gregory Durham, Mark E. Kleiman, Ginger Denison Rothrock, Ariane van der Straten Ponthoz
-
Publication number: 20180235901Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.Type: ApplicationFiled: April 19, 2018Publication date: August 23, 2018Inventors: Eun Soo LEE, Amit K. JAIN, Parminder SINGH
-
Publication number: 20180235902Abstract: It is an object of the present invention to provide a patch having practical adhesive force and cohesive force as a pharmaceutical product, and also exhibiting a fast-acting anesthetic action. The present invention provides a patch formed from an adhesive layer comprising 5% by weight or more and less than 20% by weight of a mixture of lidocaine and another local anesthetic, wherein the adhesive layer comprises at least a rubber-based pressure-sensitive adhesive and liquid paraffin and a content of a tackifier in the adhesive layer is 10% by weight or less.Type: ApplicationFiled: August 5, 2016Publication date: August 23, 2018Applicant: KANEKA CORPORATIONInventors: Tatsuyoshi TANAKA, Masaya MIZUTANI, Hiroyuki OGINO, Mitsuji AKAZAWA, Akio FUJII, Naohiro IMAI
-
Publication number: 20180235903Abstract: Described is a transdermal device comprising a backing layer; an adhesive matrix comprising fentanyl as an active agent suspended on a plurality of pressure sensitive adhesives along with a cross-linked moisture absorbent comprising cross-linked polyvinylpyrrolidone; and a release layer. Also described is a method of relieving pain, which comprising applying said transdermal device to the skin of a patient in need thereof.Type: ApplicationFiled: March 11, 2016Publication date: August 23, 2018Inventors: Jay Audett, Chee Youb Won
-
Publication number: 20180235904Abstract: A pharmaceutical composition for use in the treatment of cancer is provided. The composition includes cannabidiol (CBD) and one or more of the following compounds: D-limonene, astaxanthin, malunggay, euphorbia hirta, pao extract, copaiba and ampalaya.Type: ApplicationFiled: October 8, 2015Publication date: August 23, 2018Applicant: EARTH SCIENCE TECH, INC.Inventors: Wei R. CHEN, Chad A. CURTIS
-
Publication number: 20180235905Abstract: Embodiments of the present invention relate to the use of a therapeutically-effective amount of Olivetol to reduce, eliminate, inhibit or alleviate the psychoactive effects of THC in users of Cannabis. Further embodiments of the present invention relate to a softgel, tablet or capsule of Olivetol in combination with an edible oil.Type: ApplicationFiled: April 18, 2018Publication date: August 23, 2018Applicant: Undoo, LLCInventor: James J. Carberry
-
Publication number: 20180235906Abstract: A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an NMDA receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. The NMDA receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication. Instances of use in this manner include administration prior to an anxiety causing event, such as a medical or a dental procedure. The administration of the NMDA receptor antagonist composition is particularly useful as a premedication for adults.Type: ApplicationFiled: September 25, 2017Publication date: August 23, 2018Inventor: Stuart Weg
-
Publication number: 20180235907Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).Type: ApplicationFiled: April 16, 2018Publication date: August 23, 2018Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth UniversityInventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
-
Publication number: 20180235908Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.Type: ApplicationFiled: April 19, 2018Publication date: August 23, 2018Applicant: GRÜNENTHAL GMBHInventors: Johannes BARTHOLOMÄUS, Heinrich Kugelmann, Elisabeth Arkenau-Maric
-
Publication number: 20180235909Abstract: The use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of rheumatoid pain, especially rheumatoid arthritic pain, very especially preferably chronic rheumatoid arthritic pain.Type: ApplicationFiled: April 24, 2018Publication date: August 23, 2018Inventors: Ulrich JAHNEL, Klaus SCHIENE
-
Publication number: 20180235910Abstract: The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.Type: ApplicationFiled: September 22, 2017Publication date: August 23, 2018Inventors: Felix J. KIM, Joseph M. Salvino
-
Publication number: 20180235911Abstract: The present invention relates to a solid oral preparations comprising alogliptin and metformin fixed dose combination and to a process for preparation thereof. More particularly, it relates to a solid oral preparation of alogliptin and metformin fixed dose combination formulation which is stable and easy to manufacture.Type: ApplicationFiled: August 20, 2016Publication date: August 23, 2018Applicant: ALEMBIC PHARMACEUTICALS LIMITEDInventors: Dr. Pankaj KHAPRA, Hitesh Vaikunthbhai THAKKAR, Subhajit Chandra KAR
-
Publication number: 20180235912Abstract: The present invention relates to a novel use of a thiourea derivative and, more specifically, to a pharmaceutical composition for preventing or treating autoimmune diseases comprising a thiourea derivative as an active ingredient. The thiourea derivative according to the present invention can inhibit the transcription of inflammatory genes such as TNF-?, IL-1?, NOS2 and IL-6, and also can inhibit the activity or production of Th17 and increase the activity or production of a regulatory T cell (Treg). Thus, it is expected that the thiourea derivative may be usefully used in a pharmaceutical composition, a health food composition, etc. for the prevention, improvement or treatment of various autoimmune diseases including rheumatoid arthritis.Type: ApplicationFiled: August 12, 2016Publication date: August 23, 2018Applicant: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATIONInventors: Mi Ock LEE, Hyeung Geun PARK, Mi-La CHO, Yong-Hyun HAN, Hyeon-Ji KIM, Jin-Sil PARK
-
Publication number: 20180235913Abstract: An oral pharmaceutical formulation containing sustained-release granules including tamsulosin hydrochloride and a method of preparing the oral pharmaceutical formulation are provided. In the oral pharmaceutical formulation, the sustained-release granules includes about 10 parts to about 300 parts by weight of polyvinyl acetate, about 5 parts to about 250 parts by weight of hydroxypropyl methylcellulose, and about 1 part to about 450 parts by weight of a diluting agent with respect to 1 part by weight of tamsulosin hydrochloride, and a weight ratio of the sustained-release granules with respect to 1 part by weight of tamsulosin hydrochloride is about 360 to 495 parts by weight.Type: ApplicationFiled: February 16, 2016Publication date: August 23, 2018Applicant: HANMI PHARM. CO., LTD.Inventors: Hyung Seo KIM, Young Keun CHOI, Jung Hyun CHO, Jin Cheul KIM, Yong Il KIM, Jae Hyun PARK, Jong Soo WOO
-
Publication number: 20180235914Abstract: The present invention concerns the prototypical pharmacologic profile of GABA-stearamide, GABA-palmitamide, GABA-linoleamide and Progabide characterized by their interesting positive modulation of at least one ?-aminobutyric acid A receptor being GABA (A) and GABA (B), which are principally extrasynaptic, for treating a neurodegenerative or neurodevelopmental disease. The present invention further originating brain pro-GABAergic and anti-glutamatergic activities and also an unique pharmacological profile which antagonize all the components of the vicious circle generated in the brain by the Glutamate/GABA imbalance, with protective and preventive action against all the behavioral abnormalities, the cognitive deficits and neurotoxicities, in neurodegenerative (Alzheimer's, Parkinson's Huntington's and Multiple Sclerosis) diseases and neurodevelopmental diseases (Autism spectrum desorders and related syndroms).Type: ApplicationFiled: February 23, 2017Publication date: August 23, 2018Inventor: Alexandre Vamvakides
-
Publication number: 20180235915Abstract: The present invention concerns a package comprising an acidic citrate containing concentrate, an acidic citrate containing concentrate (or acidic citrate containing solution), and a system wherein the acidic citrate containing concentrate is included for providing a dialysis treatment. The acidic citrate containing concentrate contains citric acid and citrate in a molar ratio of 75:25 to 85:15, and has a pH of between 2 and 3.Type: ApplicationFiled: March 31, 2016Publication date: August 23, 2018Inventors: Husam MOHAMMED, Anders WIESLANDER, Viktoria HANCOCK, Karin SANDIN, Ola CARLSSON, Torbjorn LINDEN, Anna SZILAGYI
-
Publication number: 20180235916Abstract: In certain embodiments methods of promoting the replication, and/or survival, and/or function of beta cells in mammal are provided where the methods comprise administering to a mammal a GABA receptor activating ligand in conjunction with a GABAA receptor positive allosteric modulator (PAM) where the GABA receptor activating ligand is used at a lower dosage than would be used to achieve the same effect on beta cell replication, and/or survival, and/or function when used alone and/or said positive allosteric modulator is used at a subtherapeutic dosage.Type: ApplicationFiled: October 12, 2016Publication date: August 23, 2018Inventors: Daniel L. Kaufman, Jide Tian
-
Publication number: 20180235917Abstract: Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia are provided herein. Such compositions can contain synergizing amounts of leucine and/or one or more leucine metabolites in combination with nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites, and with at least one or more anti-diabetic agents. Such compositions can contain sub-therapeutic amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites, and/or sub-therapeutic amounts of one or more anti-diabetic agents that can achieve the same therapeutic efficacy as therapeutic amounts of said compositions in diabetes and/or hyperlipidemia medicaments. The composition can also reduce the side effects associated with treatment using anti-diabetic agents and/or nicotinic acid.Type: ApplicationFiled: September 23, 2015Publication date: August 23, 2018Applicant: NuSirt Sciences, Inc.Inventors: Michael ZEMEL, Antje BRUCKBAUER
-
Publication number: 20180235918Abstract: Disclosed are methods of treatment of type 1 diabetes (T1D) in subjects under standard-of-care T1D treatment, by administration of substituted long-chain amphipathic dicarboxylic acids. Also disclosed are methods of reducing standard-of-care administered dose of insulin or an insulin analogue and/or obviating the need for administration of insulin or an insulin analogue in a T1D subject by administration of substituted long-chain amphipathic dicarboxylic acids.Type: ApplicationFiled: November 30, 2017Publication date: August 23, 2018Inventor: Jacob BAR-TANA
-
Publication number: 20180235919Abstract: A method for treating or preventing atherosclerosis is disclosed by administering to a mammal a TMAO producing agent Administering a pharmaceutically effective amount of a TMAO producing agent increases trimethylamine N-oxide levels. Increased trimethylamine N-oxide levels have been found to reduce athero lesions.Type: ApplicationFiled: February 5, 2016Publication date: August 23, 2018Inventors: Aouatef Bellamine, Yuping Vivian Williamson
-
Publication number: 20180235920Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: ApplicationFiled: April 3, 2018Publication date: August 23, 2018Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI
-
Publication number: 20180235921Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.Type: ApplicationFiled: April 20, 2018Publication date: August 23, 2018Applicant: Center Laboratories, Inc.Inventors: Jui-Pao HSU, Guang-Tzuu SHANE, Meng-Ju LEE, Yi-Ping LIAO, Yu-Yin YEH
-
Publication number: 20180235922Abstract: The present invention relates to the treatment and/or prophylaxis of obesity and/or an NADPH superoxide anion (O2.?) associated cardiovascular disease.Type: ApplicationFiled: April 20, 2018Publication date: August 23, 2018Inventor: Mehrdad Ghashghaeinia
-
Publication number: 20180235923Abstract: The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.Type: ApplicationFiled: February 12, 2018Publication date: August 23, 2018Inventors: Keith CHAN, Winston Town, Shou Shan Chiang
-
Publication number: 20180235924Abstract: The invention provides compositions comprising as active agents benzoyl peroxide (BPO), adapalene and optionally clindamycin phosphate, kits and uses thereof in methods for treating skin surface condition in a subject in need thereof.Type: ApplicationFiled: August 17, 2016Publication date: August 23, 2018Applicant: SOL-GEL TECHNOLOGIES LTD.Inventors: Ofer TOLEDANO, Alon SERI-LEVY, Karine NEIMANN, Ori NOV
-
Publication number: 20180235925Abstract: Compounds having a structure of Formula I: wherein G, a, Q, L2, R1, R2, R3, R4, R5 and R6 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: November 22, 2017Publication date: August 23, 2018Inventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar, Nasrin Mawji, Carmen Adriana Banuelos, Jun Wang
-
Publication number: 20180235926Abstract: This invention relates to a method of controlling the spread of dirofilariosis, such as for example heartworm, by administering to at least one non-human animal infested with filarioid nematodes such as Dirofilaria spp or susceptible to have been infested with filarioid nematodes such as Dirofilaria spp, an effective dose of a combination of a neonicotinoid compound and a pyrethroid compound.Type: ApplicationFiled: July 8, 2016Publication date: August 23, 2018Applicant: Ceva Santè AnimaleInventors: Marie Varloud, Elizabeth Hodgkins
-
Publication number: 20180235927Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.Type: ApplicationFiled: April 24, 2018Publication date: August 23, 2018Inventors: Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost, John P. Toscano
-
Publication number: 20180235928Abstract: A method for treating diarrhea induced by a chemotherapy agent by administering a carboxylesterase 2 (CES2) inhibitor, i.e., hesperetin, naringenin, or 2?,4?-dihydroxychalcone. Also disclosed is a method for treating cancer by administering a chemotherapy agent together with hesperetin, naringenin, or 2?,4?-dihydroxychalcone. Furthermore, a composition for treating cancer is provided, the composition containing a chemotherapy agent and hesperetin, naringenin, or 2?,4?-dihydroxychalcone.Type: ApplicationFiled: August 18, 2016Publication date: August 23, 2018Inventors: Ren Kong, Hong Zhao, Stephen T.C. Wong
-
Publication number: 20180235929Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: ApplicationFiled: April 17, 2018Publication date: August 23, 2018Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
-
Publication number: 20180235930Abstract: Disclosed are methods of using nutritional compositions generally, and infant formulas specifically, to improve cognitive, brain and/or central nervous system development in an individual. The nutritional compositions include a combination of RRR-alpha tocopherol acetate, non-RRR-alpha-tocopherol stereoisomers, fat, and protein. The amount of non-RRR alpha tocopherol stereoisomers in the nutritional compositions is limited.Type: ApplicationFiled: April 25, 2018Publication date: August 23, 2018Applicant: ABBOTT LABORATORIESInventors: CHRON-SI LAI, MATTHEW KUCHAN
-
Publication number: 20180235931Abstract: The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, MK-0303 or MK-8478, in alleviating or suppressing cough (including acute, subacute and chronic cough) and urge to cough. The cough can have an unknown cause (idiopathic cough) or can be associated with any type of medical condition, such as a respiratory disorder. The NK-1 antagonist can be delivered by oral inhalation for more rapid peripheral and central antitussive action. Another antitussive agent in addition to the NK-1 antagonist can optionally be administered for the treatment of the cough or urge to cough, or the cough-associated medical condition.Type: ApplicationFiled: January 17, 2018Publication date: August 23, 2018Inventors: Steven BASTA, Paul KWON, Xiaoming ZHANG, Cyrus K. BECKER, Meenakshi S. VENKATRAMAN
-
Publication number: 20180235932Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.Type: ApplicationFiled: April 24, 2018Publication date: August 23, 2018Applicant: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA,Inventors: Dean Burkin, Ryan Wuebbles
-
Publication number: 20180235933Abstract: This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.Type: ApplicationFiled: July 27, 2016Publication date: August 23, 2018Applicant: Pfizer Inc.Inventors: Klimentina Dimitrova Pencheva, Melissa J. Birch
-
Publication number: 20180235934Abstract: Aspects of the disclosure relate to methods for treating disorders using agents for promoting hypoglossal motoneuron excitability. In some instances the disorders include obstructive sleep apnea (OSA), cataplexy, attention deficit/hyperactivity disorder (ADHD), attention deficit disorder (ADD) or depression. Related products are also included within the invention.Type: ApplicationFiled: August 18, 2016Publication date: August 23, 2018Applicant: Massachusetts Institute of TechnologyInventors: Chi-Sang Poon, Gang Song
-
Publication number: 20180235935Abstract: This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer in the treatment of cancer.Type: ApplicationFiled: August 11, 2016Publication date: August 23, 2018Inventors: Jacqueline GIBBONS, Joyce MORDENTI, Michiel DE VRIES, Walter KRAUWINKEL